Last reviewed · How we verify
NNC 0128-0000-2011 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
NNC 0128-0000-2011 (NNC 0128-0000-2011) — Novo Nordisk A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NNC 0128-0000-2011 TARGET | NNC 0128-0000-2011 | Novo Nordisk A/S | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NNC 0128-0000-2011 CI watch — RSS
- NNC 0128-0000-2011 CI watch — Atom
- NNC 0128-0000-2011 CI watch — JSON
- NNC 0128-0000-2011 alone — RSS
Cite this brief
Drug Landscape (2026). NNC 0128-0000-2011 — Competitive Intelligence Brief. https://druglandscape.com/ci/nnc-0128-0000-2011. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab